Prevention and reversal of lupus in NZB/NZW mice by costimulatory blockade with adeno-associated virus-mediated gene transfer

Arthritis and Rheumatism

Volumn 52, Issue 12, 2005, Pages 3975-3986

  Ye, Xiaojing ^a   Zhu, Tong ^a   Bastacky, Sheldon ^a   McHale, Teresa ^a   Li, Juan ^a   Xiao, Xiao ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; FLOW CYTOMETRY; GENE DELIVERY SYSTEM; GENE TRANSFER; HUMORAL IMMUNITY; IMMUNE RESPONSE; LUPUS ERYTHEMATOSUS; MEMORY CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SPLEEN CELL; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; VIRUS EXPRESSION;

ADENOVIRIDAE; ANIMALS; ANTIBODY FORMATION; ANTIGENS, CD; ANTIGENS, CD40; ANTIGENS, DIFFERENTIATION; AUTOANTIBODIES; FEMALE; GENE THERAPY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MICE; MICE, INBRED NZB; TRANSGENES;

EID: 29144512329     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21417     Document Type: Article

References (46)

1. Michet CJ Jr, McKenna CH, Elveback LR, Kaslow RA, Kurland LT. Epidemiology of systemic lupus erythematosus and other connective tissue diseases in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc 1985;60:105-13.
2. Hejaili FF, Moist LM, Clark WF. Treatment of lupus nephritis. Drugs 2003;63:257-74.
3. Andrews BS, Eisenberg RA, Theofilopoulos AN, Izui S, Wilson CB, McConahey PJ, et al. Spontaneous murine lupus-like syndromes: clinical and immunopathological manifestations in several strains. J Exp Med 1978;148:1198-215.
4. Criscione LG, Pisetsky DS. B lymphocytes and systemic lupus erythematosus. Curr Rheumatol Rep 2003;5:264-9.
5. Busser BW, Cancro MP, Laufer TM. An increased frequency of autoantibody-inducing CD4+ T cells in pre-diseased lupus-prone mice. Int Immunol 2004;16:1001-7.
6. Khoury S, Sayegh MH, Turka LA. Blocking costimulatory signals to induce transplantation tolerance and prevent autoimmune disease. Int Rev Immunol 1999;18:185-99.
7. Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001;19:225-52.
8. Yazdany J, Davis J. The role of CD40 ligand in systemic lupus erythematosus. Lupus 2004;13:377-80.
9. Slavik JM, Hutchcroft JE, Bierer BE. CD28/CTLA-4 and CD80/CD86 families: signaling and function. Immunol Res 1999;19:1-24.
10. Guerder S, Flavell RA. Costimulation in tolerance and autoimmunity. Int Rev Immunol 1995;13:135-46.
11. Parker DC, Greiner DL, Phillips NE, Appel MC, Steele AW, Durie FH, et al. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci U S A 1995;92:9560-4.
12. Arima T, Rehman A, Hickey WF, Flye MW. Inhibition by CTLA4Ig of experimental allergic encephalomyelitis. J Immunol 1996;156:4916-24.
13. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994;265:1225-7.
14. Kalled SL, Cutler AH, Datta SK, Thomas DW. Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. J Immunol 1998;160:2158-65.
15. Wang B, Li J, Xiao X. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci U S A 2000;97:13714-9.
16. Piccirillo CA, Chang Y, Prud'homme GJ. TGF-β1 somatic gene therapy prevents autoimmune disease in nonobese diabetic mice. J Immunol 1998;161:3950-6.
17. Wright JF, Qu G, Tang C, Sommer JM. Recombinant adeno-associated virus: formulation challenges and strategies for a gene therapy vector. Curr Opin Drug Discov Devel 2003;6:174-8.
18. Wagner JA, Nepomuceno IB, Messner AH, Moran ML, Batson EP, Dimiceli S, et al. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum Gene Ther 2002;13:1349-59.
19. High KA. Adeno-associated virus-mediated gene transfer for hemophilia B. Int J Hematol 2002;76:310-8.
20. 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults. Hum Gene Ther 2004;15:93-128.
21. Austin HA III, Muenz LR, Joyce KM, Antonovych TT, Balow JE. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984;25:689-95.
22. Demas GE, Nelson RJ. Lack of immunological responsiveness to photoperiod in a tropical rodent, Peromyscus aztecus hylocetes. J Comp Physiol [B] 2003;173:171-6.
23. Wang X, Huang W, Schiffer LE, Mihara M, Akkerman A, Hiromatsu K, et al. Effects of anti-CD154 treatment on B cells in murine systemic lupus erythematosus. Arthritis Rheum 2003;48:495-506.
24. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526-33.
25. Austin HA III, Muenz LR, Joyce KM, Antonovych TA, Kullick ME, Klippel JH, et al. Prognostic factors in lupus nephritis: contribution of renal histologic data. Am J Med 1983;75:382-91.
26. Spronk PE, Horst G, van der Gun BT, Limburg PC, Kallenberg CG. Anti-dsDNA production coincides with concurrent B and T cell activation during development of active disease in systemic lupus erythematosus (SLE). Clin Exp Immunol 1996;104:446-53.
27. Vyse TJ, Todd JA. Genetic analysis of autoimmune disease. Cell 1996;85:311-8.
28. Anolik J, Sanz I, Looney RJ. B cell depletion therapy in systemic lupus erythematosus. Curr Rheumatol Rep 2003;5:350-6.
29. Hahn BH, Singh RR, Wong WK, Tsao BP, Bulpitt K, Ebling FM. Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus. Arthritis Rheum 2001;44:432-41.
30. Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, Howard M. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 1994;179:305-10.
31. Quezada SA, Eckert M, Adeyi OA, Schned AR, Noelle RJ, Burns CM. Distinct mechanisms of action of anti-CD154 in early versus late treatment of murine lupus nephritis. Arthritis Rheum 2003;48:2541-54.
32. Mihara M, Tan I, Chuzhin Y, Reddy B, Budhai L, Holzer A, et al. CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus. J Clin Invest 2000;106:91-101.
33. Matsui Y, Inobe M, Okamoto H, Chiba S, Shimizu T, Kitabatake A, et al. Blockade of T cell costimulatory signals using adenovirus vectors prevents both the induction and the progression of experimental autoimmune myocarditis. J Mol Cell Cardiol 2002;34:279-95.
34. Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE, et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003;48:719-27.
35. Kalunian KC, Davis JC Jr, Merrill JT, Totoritis MC, Wofsy D, for the IDEC-131 Lupus Study Group. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:3251-8.
36. Mathieu P, Guillot C, Gerdes C, Buzelin F, Lowenstein P, Castro M, et al. Adenovirus-mediated CD40Ig expression attenuates chronic vascular rejection lesions in an aorta allotransplantation model. Transplant Proc 2002;34:743-4.
37. Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999;103:1243-52.
38. Laman JD, Claassen E, Noelle RJ. Functions of CD40 and its ligand, gp39 (CD40L). Crit Rev Immunol 1996;16:59-108.
39. Daikh DI, Finck BK, Linsley PS, Hollenbaugh D, Wofsy D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol 1997;159:3104-8.
40. Wang X, Huang W, Mihara M, Sinha J, Davidson A. Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus. J Immunol 2002;168:2046-53.
41. Daikh DI, Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol 2001;166:2913-6.
42. Guillot C, Guillonneau C, Mathieu P, Gerdes CA, Menoret S, Braudeau C, et al. Prolonged blockade of CD40-CD40 ligand interactions by gene transfer of CD40Ig results in long-term heart allograft survival and donor-specific hyporesponsiveness, but does not prevent chronic rejection. J Immunol 2002;168:1600-9.
43. Early GS, Zhao W, Burns CM. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black X New Zealand white mice: response correlates with the absence of an anti-antibody response. J Immunol 1996;157:3159-64.
44. Kundig TM, Shahinian A, Kawai K, Mittrucker HW, Sebzda E, Bachmann MF, et al. Duration of TCR stimulation determines costimulatory requirement of T cells. Immunity 1996;5:41-52.
45. Teh HS, Teh SJ. High concentrations of antigenic ligand activate and do not tolerize naive CD4 T cells in the absence of CD28/B7 costimulation. Cell Immunol 1997;179:74-83.
46. Demirci G, Amanullah F, Kewalaramani R, Yagita H, Strom TB, Sayegh MH, et al. Critical role of OX40 in CD28 and CD154-independent rejection. J Immunol 2004;172:1691-8.